ROMO1 and glioblastoma: In addition, we treated the groups of control-shRNA and Romo1-shRNA glioblastoma mice with PD-1 antibody, and found that the combination of PD-1 blockade and Romo1 inhibition significantly enhanced the inhibitory effect on the progression of glioblastoma (Control-shRNA+anti-PD-1 vs. Romo1-shRNA+anti-PD-1, p<0.05, Figure 7B and 7C).